CAS ID: | 12650-69-0 |
Molecular Formula: | C26H44O9 |
Molecular Weight: | 500.6 g/mol |
Monoisotopic Mass: | 500.2985 g/mol |
Class: | Small Molecule |
Natural Product: | No |
Other Names: | BRL 4910A | BRL-4910F | CENTANY | BRL 4910F | MUPIROCIN | PSEUDOMONIC ACID | MUPIROCIN CALCIUM | BACTROBAN |
Analysis: | Drug repositioning mechanism analysis |
InChI: | InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1 | See All |
InChI Key: | MINDHVHHQZYEEK-HBBNESRFSA-N | |
Smiles: | C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]2CO[C@@H](C\C(=C\C(=O)OCCCCCCCCC(=O)O)\C)[C@H](O)[C@@H]2O | See All |
Molfile: | Download |
Trial Record 1
ClinicalTrial ID | NCT01229553 | Disease | Cystic fibrosis |
Phase | Not Applicable | Status | Withdrawn |
First Received | October 27, 2010 | Last Verified | June 11, 2015 |
Sponsor | State University of New York - Upstate Medical University |
Trial Record 2
ClinicalTrial ID | NCT01349192 | Disease | Cystic fibrosis |
Phase | Phase 2 | Status | Terminated |
First Received | May 6, 2011 | Last Verified | May 15, 2017 |
Sponsor | University of North Carolina, Chapel Hill |
Trial Record 3
ClinicalTrial ID | NCT01594827 | Disease | Cystic fibrosis |
Phase | Phase 2 | Status | Completed |
First Received | May 9, 2012 | Last Verified | February 26, 2019 |
Sponsor | Johns Hopkins University |